Update of the position paper on arterial hypertension and erectile dysfunction.

: Sexual health is an integral part of overall health, and an active and healthy sexual life is an essential aspect of a good life quality. Cardiovascular disease and sexual health share common risk factors (arterial hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking) and common mediating mechanisms (endothelial dysfunction, subclinical inflammation, and atherosclerosis). This generated a shift of thinking about the pathophysiology and subsequently the management of sexual dysfunction. The introduction of phosphodiesterase type 5 inhibitors revolutionized the management of sexual dysfunction in men. This article will focus on erectile dysfunction and its association with arterial hypertension. This update of the position paper was created by the Working Group on Sexual Dysfunction and Arterial Hypertension of the European Society of Hypertension. This working group has been very active during the last years in promoting the familiarization of hypertension specialists and related physicians with erectile dysfunction, through numerous lectures in national and international meetings, a position paper, newsletters, guidelines, and a book specifically addressing erectile dysfunction in hypertensive patients. It was noted that erectile dysfunction precedes the development of coronary artery disease. The artery size hypothesis has been proposed as a potential explanation for this observation. This hypothesis seeks to explain the differing manifestation of the same vascular condition, based on the size of the vessels. Clinical presentations of the atherosclerotic and/or endothelium disease in the penile arteries might precede the corresponding manifestations from larger arteries. Treated hypertensive patients are more likely to have sexual dysfunction compared with untreated ones, suggesting a detrimental role of antihypertensive treatment on erectile function. The occurrence of erectile dysfunction seems to be related to undesirable effects of antihypertensive drugs on the penile tissue. Available information points toward divergent effects of antihypertensive drugs on erectile function, with diuretics and beta-blockers possessing the worst profile and angiotensin receptor blockers and nebivolol the best profile.

[1]  C. Papadopoulos,et al.  Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. , 2019, The journal of sexual medicine.

[2]  Henning Gall,et al.  CPAP therapy improves erectile function in patients with severe obstructive sleep apnea. , 2019, Sleep medicine.

[3]  M. Doumas,et al.  Erectile dysfunction: definition and size of the problem , 2018, ESC CardioMed.

[4]  D. Celermajer,et al.  Randomized Trial of CPAP and Vardenafil on Erectile and Arterial Function in Men With Obstructive Sleep Apnea and Erectile Dysfunction , 2018, The Journal of clinical endocrinology and metabolism.

[5]  M. Doumas,et al.  Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. , 2017, Current vascular pharmacology.

[6]  B. Carlberg,et al.  Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis , 2018, JAMA internal medicine.

[7]  S. Sidney,et al.  Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency , 2017, JAMA internal medicine.

[8]  G. Yumun,et al.  The Comparison of the Effects of Nebivolol and Metoprolol on Erectile Dysfunction in the Cases with Coronary Artery Bypass Surgery. , 2017, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[9]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[10]  S. Iliceto,et al.  History of erectile dysfunction as a predictor of poor physical performance after an acute myocardial infarction , 2017, European journal of preventive cardiology.

[11]  Ivy Shiue,et al.  Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015 , 2017, JAMA.

[12]  Hynek Pikhart,et al.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants , 2017, The Lancet.

[13]  Mónica González,et al.  Effects of obstructive sleep apnea and its treatment over the erectile function: a systematic review , 2016, Asian journal of andrology.

[14]  A. Manolis,et al.  Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol , 2016 .

[15]  S. Narod,et al.  Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. , 2016, The lancet. Diabetes & endocrinology.

[16]  W. Riley,et al.  Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT) , 2016, Journal of hypertension.

[17]  G. Morgia,et al.  Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.

[18]  C. Vlachopoulos,et al.  Chronotropic Incompetence and Dynamic Postexercise Autonomic Dysfunction Are Associated with the Presence and Severity of Erectile Dysfunction , 2016, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[19]  H. May,et al.  Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. , 2016, The American journal of cardiology.

[20]  A. Burri,et al.  The safety and efficacy of Avanafil, a new 2nd generation PDE5i: comprehensive review and meta-analysis , 2016, Expert opinion on drug safety.

[21]  D. Kałka,et al.  Heart rate recovery, cardiac rehabilitation and erectile dysfunction in males with ischaemic heart disease. , 2016, Anatolian journal of cardiology.

[22]  B. Dawn,et al.  Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. , 2015, European heart journal.

[23]  D. Kałka,et al.  Effect of Endurance Cardiovascular Training Intensity on Erectile Dysfunction Severity in Men With Ischemic Heart Disease , 2015, American journal of men's health.

[24]  A. Tuncel,et al.  The effect of lifestyle modification and glycemic control on the efficiency of sildenafil citrate in patients with erectile dysfunction due to type-2 diabetes mellitus , 2015, The aging male : the official journal of the International Society for the Study of the Aging Male.

[25]  S. Freedland,et al.  The association of exercise with both erectile and sexual function in black and white men. , 2015, The journal of sexual medicine.

[26]  H. Kautiainen,et al.  Factors modifying the effect of blood pressure on erectile function , 2015, Journal of hypertension.

[27]  C. Vlachopoulos,et al.  Biomarkers, erectile dysfunction, and cardiovascular risk prediction: the latest of an evolving concept , 2014, Asian journal of andrology.

[28]  C. Vlachopoulos,et al.  Clinical significance of erectile dysfunction developing after acute coronary event: exception to the rule or confirmation of the artery size hypothesis? , 2014, Asian journal of andrology.

[29]  C. Vlachopoulos,et al.  Erectile Dysfunction in Hypertension and Cardiovascular Disease , 2015 .

[30]  A. Manolis,et al.  Sexual Counseling for Patients with Cardiovascular Disease , 2015 .

[31]  M. Viigimaa Lifestyle Modification in Erectile Dysfunction and Hypertension , 2015 .

[32]  R. Kloner Testosterone and Cardiovascular Health: Safety of Treatment of Hypogonadism. , 2015, Sexual medicine reviews.

[33]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials , 2014, Journal of hypertension.

[34]  F. Wan,et al.  [Physical exercise improves erectile function in young and middle-aged men]. , 2014, Zhonghua nan ke xue = National journal of andrology.

[35]  C. Vlachopoulos,et al.  Management of erectile dysfunction in hypertension: Tips and tricks. , 2014, World journal of cardiology.

[36]  P. Boström,et al.  High-intensity physical activity, stable relationship, and high education level associate with decreasing risk of erectile dysfunction in 1,000 apparently healthy cardiovascular risk subjects. , 2014, The journal of sexual medicine.

[37]  G. Palleschi,et al.  Severe obstructive sleep apnoea syndrome and erectile dysfunction: a prospective randomised study to compare sildenafil vs. nasal continuous positive airway pressure , 2014, International journal of clinical practice.

[38]  Anne W. Taylor,et al.  Predictors of sexual dysfunction incidence and remission in men. , 2014, The journal of sexual medicine.

[39]  A. Traish,et al.  Death by testosterone? We think not! , 2014, The journal of sexual medicine.

[40]  S. Greenland,et al.  Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men , 2014, PloS one.

[41]  Philippe Van De Borne,et al.  Guidelines for the management of arterial hypertension , 2014 .

[42]  K. Channer,et al.  Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. , 2013, European journal of endocrinology.

[43]  G. Grunwald,et al.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.

[44]  R. Kloner,et al.  The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician , 2013, International journal of clinical practice.

[45]  A. Dominiczak,et al.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. , 2013, Journal of hypertension.

[46]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[47]  J. Faintuch,et al.  Sexual hormones and erectile function more than 6 years after bariatric surgery. , 2013, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[48]  M. Sanford Avanafil: A Review of Its Use in Patients with Erectile Dysfunction , 2013, Drugs & Aging.

[49]  C. Vlachopoulos,et al.  Erectile dysfunction in the cardiovascular patient. , 2013, European heart journal.

[50]  M. Viigimaa,et al.  Combined Antihypertensive Therapy and Sexual Dysfunction: Terra Incognita , 2013, Cardiology.

[51]  R. Ma,et al.  The Effect of Combined Antihypertensive Treatment (Felodipine with Either Irbesartan or Metoprolol) on Erectile Function: A Randomized Controlled Trial , 2013, Cardiology.

[52]  E. Steinke How Can Heart Failure Patients and Their Partners Be Counseled on Sexual Activity? , 2013, Current Heart Failure Reports.

[53]  J. Murabito,et al.  Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all‐cause mortality in elderly men from the Framingham Heart Study , 2013, Clinical endocrinology.

[54]  R. Jörres,et al.  Long-term changes of sexual function in men with obstructive sleep apnea after initiation of continuous positive airway pressure. , 2013, The journal of sexual medicine.

[55]  P. Macdonald,et al.  Erectile Dysfunction Severity as a Risk Marker for Cardiovascular Disease Hospitalisation and All-Cause Mortality: A Prospective Cohort Study , 2013, PLoS medicine.

[56]  C. Vlachopoulos,et al.  Prediction of Cardiovascular Events and All-Cause Mortality With Erectile Dysfunction: A Systematic Review and Meta-Analysis of Cohort Studies , 2012, Circulation. Cardiovascular quality and outcomes.

[57]  T. Jørgensen,et al.  Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk: The MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project , 2012, Hypertension.

[58]  G. Chrysant,et al.  The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension , 2012, Journal of clinical hypertension.

[59]  R. Kloner,et al.  The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. , 2012, Mayo Clinic proceedings.

[60]  L. Shi,et al.  Losartan improves erectile dysfunction in diabetic patients: a clinical trial , 2012, International Journal of Impotence Research.

[61]  N. Smith,et al.  Testosterone treatment and mortality in men with low testosterone levels. , 2012, The Journal of clinical endocrinology and metabolism.

[62]  W. Clark,et al.  Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. , 2012, Urology.

[63]  Adam B. Shrewsberry,et al.  Exercise is associated with better erectile function in men under 40 as evaluated by the International Index of Erectile Function. , 2012, The journal of sexual medicine.

[64]  R. Ma,et al.  Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension , 2012, Journal of hypertension.

[65]  R. Costabile,et al.  10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. , 2012, The journal of sexual medicine.

[66]  Marta Drummond,et al.  Obstructive sleep apnea symptoms beyond sleepiness and snoring: effects of nasal APAP therapy , 2012, Sleep and Breathing.

[67]  G. Forti,et al.  Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. , 2011, European journal of endocrinology.

[68]  L. Qin,et al.  Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. , 2011, Journal of the American College of Cardiology.

[69]  A. Araujo,et al.  Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis , 2011 .

[70]  J. Hartikainen,et al.  Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis , 2011, BMC cardiovascular disorders.

[71]  D. W. Wright,et al.  Progress in sexual counseling by cardiac nurses, 1994 to 2009. , 2011, Heart & lung : the journal of critical care.

[72]  M. Böhm,et al.  Cardiovascular risk, drugs and erectile function – a systematic analysis , 2011, International journal of clinical practice.

[73]  P. Anyfanti,et al.  Hypertension and sexual dysfunction: time to act. , 2011, Journal of hypertension.

[74]  H. Sperling,et al.  Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. , 2011, The journal of sexual medicine.

[75]  L. Ignarro,et al.  A multifaceted approach to maximize erectile function and vascular health. , 2010, Fertility and sterility.

[76]  Rosanna Abbate,et al.  Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. , 2010, The American journal of clinical nutrition.

[77]  J. González-Juanatey,et al.  Erectile Dysfunction May Improve by Blood Pressure Control in Patients with High-Risk Hypertension , 2010, Postgraduate medicine.

[78]  J. Zumbé,et al.  The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. , 2010, The journal of sexual medicine.

[79]  P. Cuevas,et al.  Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. , 2010, The journal of sexual medicine.

[80]  A. Jette,et al.  Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[81]  Amy T. Wang,et al.  Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[82]  F. Montorsi,et al.  Erectile dysfunction and coronary artery disease prediction: evidence‐based guidance and consensus , 2010, International journal of clinical practice.

[83]  A. Marchiori,et al.  Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. , 2010, The journal of sexual medicine.

[84]  Zhiping Wang,et al.  Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a meta-analysis , 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

[85]  S. Yusuf,et al.  Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONT , 2010, Circulation.

[86]  P. Conthe,et al.  Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. , 2010, Cardiovascular therapeutics.

[87]  I. Fergus Antihypertensive pharmacotherapy: adverse effects of medications promote nonadherence. , 2009, Journal of the cardiometabolic syndrome.

[88]  A. Dominiczak,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. , 2009, Journal of hypertension.

[89]  R. Jörres,et al.  Sleep apnea is an independent correlate of erectile and sexual dysfunction. , 2009, The journal of sexual medicine.

[90]  T. Wilt,et al.  Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. , 2009, Urology.

[91]  T. Travison,et al.  Erectile dysfunction and mortality. , 2009, The journal of sexual medicine.

[92]  Darya L. Zabelina,et al.  The Effect of Age on Weight‐Related Quality of Life in Overweight and Obese Individuals , 2009, Obesity.

[93]  T. Wadden,et al.  Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. , 2009, The journal of sexual medicine.

[94]  S. Lamina,et al.  Managing erectile dysfunction in hypertension: the effects of a continuous training programme on biomarker of inflammation , 2009, BJU international.

[95]  S. Lamina,et al.  Therapeutic Effect of an Interval Exercise Training Program in the Management of Erectile Dysfunction in Hypertensive Patients , 2009, Journal of clinical hypertension.

[96]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[97]  A. Manolis,et al.  Hypertension and sexual dysfunction , 2009 .

[98]  J. Kaufman,et al.  Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. , 2009, European urology.

[99]  F. Montorsi,et al.  Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[100]  M. O'Leary,et al.  Sexual dysfunction is common in the morbidly obese male and improves after gastric bypass surgery. , 2008, Journal of the American College of Surgeons.

[101]  A. Manolis,et al.  Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications , 2008, Journal of hypertension.

[102]  I. Thompson,et al.  Investigation, treatment and monitoring of late-onset hypogonadism in males , 2008, European journal of endocrinology.

[103]  Kwangsung Park,et al.  An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. , 2008, The journal of sexual medicine.

[104]  C. H. Lee,et al.  Erectile dysfunction and disease-specific quality of life in patients with obstructive sleep apnea , 2008, International Journal of Impotence Research.

[105]  G. Cocco Erectile Dysfunction after Therapy with Metoprolol: The Hawthorne Effect , 2008, Cardiology.

[106]  M. Böhm,et al.  Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome , 2008, International Journal of Impotence Research.

[107]  M. Miner,et al.  Vardenafil in men with stable statin therapy and dyslipidemia. , 2008, The journal of sexual medicine.

[108]  M. Böhm,et al.  Nebivolol, but Not Metoprolol, Improves Endothelial Function of the Corpus Cavernosum in Apolipoprotein E-Knockout Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.

[109]  K. Steinhauser,et al.  Selective adherence to antihypertensive medications as a patient-driven means to preserving sexual potency , 2008, Patient preference and adherence.

[110]  Erasmus Mc,et al.  Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study , 2008, International Journal of Impotence Research.

[111]  M. Mitchell,et al.  Hemodynamic Interaction Between a Daily Dosed Phosphodiesterase 5 Inhibitor, Tadalafil, and the α‐Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle‐Aged Healthy Male Subjects , 2007, Journal of clinical pharmacology.

[112]  R. Schwinger,et al.  Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum. , 2007, Life sciences.

[113]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[114]  R. Schwinger,et al.  NITRIC OXIDE, ERECTILE DYSFUNCTION AND BETA‐BLOCKER TREATMENT (MR NOED STUDY): BENEFIT OF NEBIVOLOL VERSUS METOPROLOL IN HYPERTENSIVE MEN , 2007, Clinical and experimental pharmacology & physiology.

[115]  K. Greenlund,et al.  Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. , 2007, American journal of hypertension.

[116]  K. Karkoulias,et al.  Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a comparative study of their efficacy and safety and the patient's satisfaction with treatment. , 2007, Asian journal of andrology.

[117]  L. Hazell,et al.  An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease , 2007, BJU international.

[118]  K. Karkoulias,et al.  The impact of long-term conventional treatment for overlap syndrome (obstructive sleep apnea and chronic obstructive pulmonary disease) on concurrent erectile dysfunction. , 2007, Respiratory medicine.

[119]  M. Litwin,et al.  Health-related quality of life in men with erectile dysfunction , 1998, Journal of General Internal Medicine.

[120]  K. Narkiewicz,et al.  European Society of Hypertension Scientific Newsletter: Update on Hypertension Management , 2007 .

[121]  Edward D. Kim,et al.  Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. , 2007, The journal of sexual medicine.

[122]  G. Bianchi,et al.  Immediate improvement in penile hemodynamics after cessation of smoking: previous results. , 2007, Urology.

[123]  V. Montori,et al.  Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. , 2007, Mayo Clinic proceedings.

[124]  O. Mazza,et al.  In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats. , 2006, American journal of hypertension.

[125]  T. Tammela,et al.  The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. , 2006, The Journal of urology.

[126]  S. Douma,et al.  Female sexual dysfunction in essential hypertension: a common problem being uncovered , 2006, Journal of hypertension.

[127]  F. Montorsi,et al.  First‐dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY‐I , 2006, International journal of clinical practice.

[128]  F. Montorsi,et al.  Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. , 2006, European urology.

[129]  D. Ziegler,et al.  Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. , 2006, The journal of sexual medicine.

[130]  C. Napoli,et al.  Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. , 2006, Nitric oxide : biology and chemistry.

[131]  O. Mazza,et al.  The effect of different antihypertensive drugs on cavernous tissue in experimental chronic renal insufficiency. , 2006, Journal of nephrology.

[132]  J. Lefante,et al.  Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications , 2006, Current opinion in cardiology.

[133]  R. Kloner,et al.  Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. , 2006, The American journal of cardiology.

[134]  S. Kaplan,et al.  Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. , 2006, Urology.

[135]  S. Douma,et al.  Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. , 2006, Journal of andrology.

[136]  J. Mulhall,et al.  Defining association between sleep apnea syndrome and erectile dysfunction. , 2006, Urology.

[137]  T. Demir Prevalence of erectile dysfunction in patients with metabolic syndrome , 2006, International journal of urology : official journal of the Japanese Urological Association.

[138]  S. Douma,et al.  Sexual Dysfunction in Essential Hypertension: Myth or Reality? , 2006, Journal of clinical hypertension.

[139]  S. Douma,et al.  Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. , 2006, Asian journal of andrology.

[140]  R. Kloner Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. , 2005, The American journal of cardiology.

[141]  F. Montorsi,et al.  The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. , 2005, The American journal of cardiology.

[142]  I. Thompson,et al.  Erectile dysfunction and subsequent cardiovascular disease. , 2005, JAMA.

[143]  C. Vlachopoulos,et al.  Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. , 2005, European urology.

[144]  R. Kloner,et al.  The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. , 2005, British journal of clinical pharmacology.

[145]  W. Kupper,et al.  Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. , 2005, The journal of sexual medicine.

[146]  T. Mclaughlin,et al.  Evaluation of Erectile Dysfunction Therapy in Patients Previously Nonadherent to Long-Term Medications: A Retrospective Analysis of Prescription Claims , 2005, American journal of therapeutics.

[147]  Martin L. Lee,et al.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[148]  B. Meibohm,et al.  The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction , 2005, Journal of clinical pharmacology.

[149]  R. Kloner,et al.  Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy , 2005, International Journal of Impotence Research.

[150]  J. Bancroft The endocrinology of sexual arousal. , 2005, The Journal of endocrinology.

[151]  C. Bulpitt,et al.  Quality of life and antihypertensive effect with nebivolol and losartan. , 2005, American Journal of Hypertension.

[152]  M. Mittleman,et al.  Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. , 2005, The American journal of cardiology.

[153]  R. Cumming,et al.  Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men , 2005, The Lancet.

[154]  C. Guilleminault,et al.  Erectile dysfunction, obstructive sleep apnea syndrome and nasal CPAP treatment. , 2005, Sleep medicine.

[155]  D. Tekes-Manova,et al.  Association between erectile dysfunction and sleep disorders measured by self-assessment questionnaires in adult men. , 2005, The journal of sexual medicine.

[156]  J. Cappelleri,et al.  The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience , 2005, International Journal of Impotence Research.

[157]  M. Wajngarten,et al.  Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. , 2005, International braz j urol : official journal of the Brazilian Society of Urology.

[158]  G. Pillar,et al.  Predictors of erectile function improvement in obstructive sleep apnea patients with long-term CPAP treatment , 2005, International Journal of Impotence Research.

[159]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[160]  M. Zoghi,et al.  A Randomised Comparison of the Effects of Nebivolol and Atenolol with and without Chlorthalidone on the Sexual Function of Hypertensive Men , 2005, Clinical drug investigation.

[161]  Hao Wang,et al.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. , 2005, The American journal of cardiology.

[162]  S. Madersbacher,et al.  Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. , 2005, European urology.

[163]  A. Mehrsai,et al.  Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study , 2004, BJU international.

[164]  G. Mancia,et al.  Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. , 2004, American journal of hypertension.

[165]  R. Kloner,et al.  Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. , 2004, The Journal of urology.

[166]  F. Montorsi,et al.  Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. , 2004, The journal of sexual medicine.

[167]  R. Marfella,et al.  Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. , 2004, JAMA.

[168]  K. Karkoulias,et al.  Erectile dysfunction in men with obstructive sleep apnea syndrome: a randomized study of the efficacy of sildenafil and continuous positive airway pressure , 2004, International Journal of Impotence Research.

[169]  I. Stella,et al.  Protection of cavernous tissue in male spontaneously hypertensive rats. Beyond blood pressure control. , 2004, American journal of hypertension.

[170]  T. Tammela,et al.  Effects of age, comorbidity and lifestyle factors on erectile function: Tampere Ageing Male Urological Study (TAMUS). , 2004, European urology.

[171]  C. Niederberger,et al.  The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence oSf erectile dysfunction and related health concerns in the general population , 2004, Current medical research and opinion.

[172]  G. Pillar,et al.  Severe, but not mild, obstructive sleep apnea syndrome is associated with erectile dysfunction. , 2004, Urology.

[173]  C. Stief,et al.  Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction , 2004, International journal of clinical practice.

[174]  F. Montorsi,et al.  Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. , 2004, European urology.

[175]  L. Ruilope,et al.  Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. , 2004, American journal of hypertension.

[176]  C. Pepine,et al.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease , 2004, The American journal of cardiology.

[177]  F. Parazzini,et al.  Determinants of erectile dysfunction risk in a large series of Italian men attending andrology clinics. , 2004, European urology.

[178]  R. Kloner,et al.  Time course of the interaction between tadalafil and nitrates. , 2003, Journal of the American College of Cardiology.

[179]  G. Rosano,et al.  Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. , 2003, European heart journal.

[180]  F. Montorsi,et al.  Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. , 2003, European urology.

[181]  E. Rimm,et al.  Sexual Function in Men Older Than 50 Years of Age: Results from the Health Professionals Follow-up Study , 2003, Annals of Internal Medicine.

[182]  J. Sánchez-Cruz,et al.  Male erectile dysfunction and health-related quality of life. , 2003, European urology.

[183]  L. Lindholm,et al.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) , 2003, Journal of hypertension.

[184]  O. Hess,et al.  Sexual activity in hypertensive men , 2003, Journal of Human Hypertension.

[185]  E. Moreira,et al.  Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study , 2003, International Journal of Impotence Research.

[186]  S. Lewington Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[187]  I. Goldstein,et al.  Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. , 2003, Diabetes care.

[188]  A. Fugl-Meyer,et al.  Epidemiology of erectile dysfunction , 2003, International Journal of Impotence Research.

[189]  F. Montorsi,et al.  Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. , 2003, Diabetes care.

[190]  R. Düsing Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men , 2003, Blood pressure. Supplement.

[191]  R. Norton,et al.  Blood pressure and cardiovascular disease in the Asia Pacific region , 2003 .

[192]  E. Moreira,et al.  Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. , 2003, Urology.

[193]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[194]  M. Mitchell,et al.  Overview of the cardiovascular effects of tadalafil , 2002 .

[195]  I. Sáenz de Tejada,et al.  Effects of tadalafil on erectile dysfunction in men with diabetes. , 2002, Diabetes care.

[196]  W. Hellstrom,et al.  Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. , 2002, Journal of andrology.

[197]  D. Ramos,et al.  Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. , 2002, Urology.

[198]  A. Burnett,et al.  The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. , 2002, Urology.

[199]  A. Ciampi,et al.  Determinants of discontinuation of new courses of antihypertensive medications. , 2002, Journal of clinical epidemiology.

[200]  D. Wysowski,et al.  Comparison of reported and expected deaths in sildenafil (Viagra) users. , 2002, The American journal of cardiology.

[201]  R. Fogari,et al.  Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men , 2002, European Journal of Clinical Pharmacology.

[202]  G. Muirhead,et al.  Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. , 2002, British journal of clinical pharmacology.

[203]  A. Kadıoğlu,et al.  Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. , 2002, European urology.

[204]  G. De Backer,et al.  Prevalence and correlates of erectile dysfunction in a population-based study in Belgium. , 2002, European urology.

[205]  M. Fujisawa,et al.  EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS TREATED FOR ERECTILE DYSFUNCTION WITH VIAGRA (SILDENAFIL CITRATE) USING SF-36 SCORE , 2002, Archives of andrology.

[206]  A. Kadıoğlu,et al.  (TURKISH ERECTILE DYSFUNCTION PREVALENCE STUDY GROUP). PREVALENCE AND CORRELATES OF ERECTILE DYSFUNCTION IN TURKEY: A POPULATION-BASED STUDY , 2002 .

[207]  A. Boulton,et al.  Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus , 2001, Diabetologia.

[208]  J. Sánchez-Cruz,et al.  Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. , 2001, The Journal of urology.

[209]  C. Ferrario,et al.  Sexual Dysfunction in Hypertensive Patients Treated with Losartan , 2001, The American journal of the medical sciences.

[210]  S. Shakir,et al.  Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England , 2001, BMJ : British Medical Journal.

[211]  K. Marumo,et al.  Age‐related prevalence of erectile dysfunction in Japan: Assessment by the International Index of Erectile Function , 2001, International journal of urology : official journal of the Japanese Urological Association.

[212]  R. Fogari,et al.  Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. , 2001, American journal of hypertension.

[213]  R. Kloner,et al.  Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. , 2001, American journal of hypertension.

[214]  C. Persson,et al.  EFFICACY AND SAFETY OF SILDENAFIL CITRATE FOR THE TREATMENT OF ERECTILE DYSFUNCTION IN MEN WITH CARDIOVASCULAR DISEASE , 2001, International journal of clinical practice.

[215]  T. H. Klotz,et al.  Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’ , 2000, International Journal of Impotence Research.

[216]  A. Zanchetti,et al.  Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy , 2000, Journal of hypertension.

[217]  J. McKinlay,et al.  The worldwide prevalence and epidemiology of erectile dysfunction , 2000, International Journal of Impotence Research.

[218]  R. Kloner Cardiovascular risk and sildenafil. , 2000, The American journal of cardiology.

[219]  D. Webb,et al.  Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. , 2000, Journal of the American College of Cardiology.

[220]  A. Araujo,et al.  Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. , 2000, The Journal of urology.

[221]  C. Conti,et al.  Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. , 1999, The American journal of cardiology.

[222]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[223]  E. Laumann,et al.  Sexual dysfunction in the United States: prevalence and predictors. , 1999, JAMA.

[224]  J. Feenstra,et al.  Acute myocardial infarction associated with sildenafil , 1998, The Lancet.

[225]  H. Intili,et al.  Self-esteem and depression in men who present with erectile dysfunction. , 1998, Urologic nursing.

[226]  A. Morales,et al.  Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction , 1998, International Journal of Impotence Research.

[227]  I. Osterloh,et al.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. , 1997, Urology.

[228]  R. Rosen Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. , 1997, Blood pressure. Supplement.

[229]  C. Lewis,et al.  Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) , 1997, Hypertension.

[230]  H A Feldman,et al.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. , 1994, The Journal of urology.

[231]  D J Reda,et al.  Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo , 1993 .

[232]  J. Bancroft,et al.  The effects of exogenous testosterone on sexuality and mood of normal men. , 1992, The Journal of clinical endocrinology and metabolism.

[233]  M. Blaufox,et al.  Effect of antihypertensives on sexual function and quality of life: the TAIM Study. , 1991, Annals of internal medicine.

[234]  J. Clive,et al.  Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. , 1988, Archives of internal medicine.

[235]  A. Riley,et al.  The Prevalence of Sexual Dysfunction in Male and Female Hypertensive Patients , 1987 .

[236]  ADVERSE REACTIONS TO BENDROFLUAZIDE AND PROPRANOLOL FOR THE TREATMENT OF MILD HYPERTENSION Report of Medical Research Council Working Party on Mild to Moderate Hypertension , 1981, The Lancet.

[237]  J. Baker,et al.  Side-effects of antihypertensive treatment: a placebo-controlled study. , 1978, Clinical science and molecular medicine. Supplement.

[238]  C. Dollery,et al.  Change in symptoms of hypertensive patients after referral to hospital clinic. , 1976, British heart journal.